Company: CRL
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001100682-25-000034
Chunk: 40

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 2
Chunk 40
---
 primarily driven by the following activity:

•Net proceeds of $85.7 million from our Credit Facility

•Treasury stock purchases of $350.0 million associated with our stock repurchase program and $9.9 million due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements

•Payment of $21.8 million associated with contingent consideration related to the acquisition of Noveprim

•Payment of $19.1 million for the remaining 8% equity interest in Vital River 

For the six months ended June 29, 2024, net cash provided by financing activities was primarily driven by the following activity:

•Net repayments of $252.4 million from our Credit Facility

•Net proceeds from exercises of employee stock options of $22.3 million

•Treasury stock purchases of $18.3 million made due to the netting of common stock upon vesting of stock-based awards in order to satisfy individual statutory tax withholding requirements

•Payment of $12.0 million for the remaining 10% equity interest in an other redeemable noncontrolling interest

Financing and Market Risk

We are exposed to market risk from changes in interest rates and currency exchange rates, which could affect our future results of operations and financial condition. We manage our exposure to these risks through our regular operating and financing activities.

Amounts outstanding under our Credit Facility and our Senior Notes were as follows:June 28, 2025December 28, 2024(in thousands)Revolving facility$813,002 $714,948 4.25% Senior Notes due 2028500,000 500,000 3.75% Senior Notes due 2029500,000 500,000 4.00% Senior Notes due 2031500,000 500,000 Total$2,313,002 $2,214,948 

36 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

The Credit Facility provides for up to $2.0 billion of multi-currency revolving credit and has a maturity date of December 2029, with no required scheduled payment before that date. The interest rates applicable to the revolving facility are equal to (A) for revolving loans denominated in U.S. dollars, at our option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0